The Rising Burden of Osteosarcopenia in Older Adults: A Narrative Review of Pathophysiology, Diagnostic Challenges, and Therapeutic Perspectives Authors: Javeria Taj, Rabia Zafar, Joshua Ekouo, Ayesha Junaid, Dujardin Makeda, Kinza Latif, Hermann Yokolo Published: 2026 ABSTRACT ABSTRACTBackground and AimsOsteosarcopenia, defined as the coexistence of osteoporosis and sarcopenia, is an emerging geriatric syndrome linked to the musculoskeletal decline associated with aging. It is correlated with an increased risk of falls, fractures, disability, and mortality. This review aims to synthesize the emerging concepts, underlying mechanisms, epidemiology, diagnostic challenges, and current therapeutic strategies for osteosarcopenia.MethodsA narrative review was conducted using the PubMed, Scopus, and Google Scholar databases. The keywords used were: osteosarcopenia, sarcopenia, osteoporosis, frailty, and related terms. Relevant peer‐reviewed studies and reports from international organizations were included. The selected articles, addressing definitions, pathophysiology, epidemiology, diagnosis, and management, underwent thematic analysis.ResultsOsteosarcopenia affects approximately 18% to 20% of older adults. Its prevalence increases with age and is higher in women. Osteosarcopenia results from mechanisms common to both bones and muscles, including chronic inflammation, hormonal decline, genetic and epigenetic factors, dysregulated signaling pathways, and the interplay between muscles and bones. Risk factors include age, sedentary lifestyle, malnutrition, chronic diseases, and endocrine disorders. Diagnosis remains complex due to the lack of standardized criteria and relies on separate assessments such as bone densitometry (DXA) for bone density and functional tests for muscle strength. The emergence of biomarkers and composite indices holds promise for improved detection. Management primarily involves resistance training, nutritional optimization (protein, calcium, vitamin D), and anti‐osteoporosis medications. However, no treatment simultaneously targets both components, and pharmacological options remain limited.ConclusionOsteosarcopenia represents a major and growing public health problem in aging populations. Despite progress in understanding its pathophysiology, gaps persist in standardized diagnosis and integrated treatment. Multidisciplinary approaches combining physical exercise, nutrition, and pharmacotherapy, as well as future research on unified diagnostic criteria and targeted therapies, are essential to reduce its impact and improve the functional abilities of older adults. Abbreviations Angiotensin‐Converting Enzyme Inhibitors Activin Receptor Type IIB‐Fc Fusion Protein Alkaline Phosphatase bone mineral density Chemokine (C‐X‐C motif) Ligand dual‐energy X‐ray absorptiometry Global Leadership Initiative in Sarcopenia Glucagon‐Like Peptide‐1 Hip‐Padua Osteosarcopenia (model) High‐Intensity Dynamic Resistance Training β‐hydroxy β‐methylbutyrate Interleukin‐6 Lymphotoxin Alpha Mitogen‐Activated Protein Kinase Mesenchymal stem cell Nuclear Factor Kappa B osteocalcin Osteoprotegerin ovariectomized Programmed Cell Death 4 progressive resistance training Receptor Activator of Nuclear Factor κB Ligand Runt‐Related Transcription Factor 2 selective androgen receptor modulators Short‐Chain Fatty Acid Single‐cell RNA sequencing standard deviation sirtuin sclerostin Tumor Necrosis Factor Alpha vitamin D receptor Vascular Endothelial Growth Factor A World Health Organization Introduction The World Health Organization (WHO) has identified aging as one of the most significant challenges of the twenty‐first century around the world [1]. Organ function progressively declines with age, a significant manifestation of musculoskeletal system disease leading to frailty and impaired mobility [2]. Numerous studies have consistently demonstrated that aging significantly contributes to the development of various musculoskeletal disorders [3]. Osteosarcopenia, an emerging geriatric syndrome mainly, describes the co‐existence of osteopenia/osteoporosis and sarcopenia [4]. According to WHO criteria, osteopenia is defined as a bone mineral density (BMD) between 1.0 and 2.5 standard deviations (SD) below the mean value of a young reference population, whereas 2.5 (SD) or more below the mean for young normal adult defines osteoporosis, determined by dual‐energy X‐ray absorptiometry (DXA) [5]. According to Global Leadership Initiative in Sarcopenia (GLIS) steering committee, sarcopenia is the concurrent combination of reduced muscle mass and muscle strength [6]. Osteosarcopenia, first coined by Duque and his colleagues, has been correlated with a high incidence of falls, fragility fractures, morbidity and mortality [7]. Sarcopenia and osteoporosis share similar risk factors and biological mechanism that significantly lead to physical disability and dependence in older adults. Due to their combined detrimental impact on the musculoskeletal apparatus, some researchers refer to them as a “dangerous duo.” For instance, a 4‐year follow‐up study of older Japanese adults found a high prevalence of sarcopenia among individuals with osteoporosis, and vice versa [8]. Methodology This narrative review explores the pathophysiology, clinical phenotypes, epidemiology, diagnostic challenges, and management of osteosarcopenia. A comprehensive literature search was performed in PubMed, Scopus, and Google Scholar. Keywords included: osteosarcopenia, osteoporosis, sarcopenia, frailty, musculoskeletal aging, bone‐muscle crosstalk, falls, fractures, resistance training, nutrition, and pharmacological therapies. In addition to peer‐reviewed articles, official documents from the World Health Organization (WHO), the International Osteoporosis Foundation (IOF), and the European Working Group on Sarcopenia in Older People (EWGSOP2) were considered. Inclusion criteria included studies investigating definitions, prevalence, mechanisms, outcomes, and preventive or therapeutic interventions related to osteosarcopenia, while non‐English sources, irrelevant reports, and isolated case studies were excluded. Eligible publications were analyzed and synthesized thematically along the following axes: introduction, pathophysiology, evolving concepts, epidemiology, risk factors, diagnosis, therapeutic strategies, integrated care, and future perspectives. This approach provided a broad and multidisciplinary overview of osteosarcopenia as an emerging geriatric syndrome, highlighting knowledge gaps and illustrating directions for clinical practice and research. Evolving Concepts and Clinical Phenotypes Previously considered as two separate syndromes, osteoporosis and sarcopenia are now recognized as a combined clinical entity reflecting a complex interaction between muscle and bone: osteosarcopenia. This evolution in concept reflects a better understanding of the biological mechanisms showing that muscle and bone communicate via mechanical stress, cytokines, and hormones. Progressive loss of muscle and bone with aging raises the likelihood of fractures, falls, and loss of independence; this suggests a common mechanism rather than two distinct diseases [9, 10]. More recently, the concept has expanded to include the notion of “obese sarcopenia,” where the concurrent presence of excessive fat mass (obesity) exacerbates frailty, further increasing vulnerability and functional decline, and thereby contributing to higher risks of falls and fractures. This decline reflects a broader spectrum of frailty that affects older persons' mobility and self‐reliance, such as diminished muscle strength, low bone density, and increasing fat mass [11, 12]. Osteosarcopenia shows up clinically as reduced grip strength, pace of walking, and functional capacity, that may end up in falls, loss of independence, and increased dependency. This accentuates the significance for multidisciplinary care and integrated diagnosis [13, 14]. Pathophysiology It is important to understand the mechanisms involved in the pathophysiology of osteosarcopenia to discover novel therapeutic targets and management strategies. The summary table of pathophysiology is given in. miRNA Salamanna et al. reported that the microRNAs commonly dysregulated in the pathophysiology of osteosarcopenia are miR‐155, miR‐206, and miR‐328, all of which were found to be consistently downregulated across multiple studies [15]. Furthermore, miR‐29b appears to support osteogenesis by downregulating negative regulators like HDAC4, TGFβ3, and DUSP2, thereby facilitating matrix mineralization [16]. However, in ovariectomized (OVX) models, miR‐29b‐3p was found to inhibit osteogenic differentiation via SIRT1 suppression, and additionally reducing the expression of key markers such as ALP, OCN, and RUNX2, suggesting a pathological context‐dependent dual role [17]. miR‐29b contributes to muscle atrophy by inducing Atrogin‐1 and Murf‐1 expressions and interfering with the IGF1‐Akt/FoxO3A/mTOR signaling pathway [18]. By FoxO3a‐mediated MuRF‐1/Atrogin‐1 activation and IGF‐1 downregulation, miR‐128 promotes muscle atrophy whilst limiting bone formation via SIRT6 [19, 20]. MiR‐21 exhibits a dual role in bone homeostasis, stimulating bone regeneration through PTEN/PI3K/Akt/HIF‐1α while also regulating osteoclastogenesis through PDCD4 and RANKL/OPG balance [21, 22]. Bone‐derived exosome miR‐486‐5p controls muscle physiology, whereas muscle‐derived exosomal miR‐34a and miR‐27a‐3p affect bone metabolism, according to Bo Zhang et al. [23]. (Table 1) Table 1miRNA roles in osteosarcopenia.miRNABone effectsMuscle effectsmiR‐155, miR‐206, miR‐328Consistently downregulated in osteosarcopenia; implicated in impaired osteoblast activityDownregulated across multiple studies; contribute to muscle–bone crosstalk disruptionmiR‐29bPromotes osteogenesis via downregulation of HDAC4, TGFβ3, DUSP2; context‐dependent inhibition of osteogenic differentiation via SIRT1 suppression (OVX models)Induces muscle atrophy via Atrogin‐1 and MuRF‐1 upregulation; interferes with IGF1‐Akt/FoxO3A/mTOR signalingmiR‐128Limits bone formation via SIRT6 suppressionPromotes muscle atrophy through FoxO3a‐mediated MuRF‐1/Atrogin‐1 activation and IGF‐1 downregulationmiR‐21Dual role: promotes bone regeneration via PTEN/PI3K/Akt/HIF‐1α; regulates osteoclastogenesis via PDCD4 and RANKL/OPG balanceContributes to atrophy‐related signalingmiR‐486‐5p (bone‐derived exosomal) Secreted by bone; modulates skeletal muscle physiology via exosomal signalingControls muscle physiology through bone‐to‐muscle exosomal communicationmiR‐34a, miR‐27a‐3p (muscle‐derived exosomal) Affect bone metabolism via muscle‐to‐bone exosomal signalingSecreted by muscle; participate in bidirectional bone–muscle crosstalkJohn Wiley & Sons, Ltd. miRNA roles in osteosarcopenia. Taken together, the evidence reviewed above highlights microRNAs as critical post‐transcriptional regulators coordinating the reciprocal interactions between bone and muscle in the pathogenesis of osteosarcopenia. Genetic Polymorphisms Variants in GLYAT, METTL21C, myostatin, ACTN3, PGC‐1α, and MEF2C affect the risk of osteosarcopenia by controlling skeletal integrity, muscle function, and energy metabolism [24]. SREBF1, which mainly controls lipid metabolism, has opposite impacts on bone and muscle. The rs7501812 G‐allele enhances osteoblast mineralization but suppresses MYOD1, MYOG, and MEF2C, which inhibits myoblast proliferation and causes osteosarcopenia [25]. By promoting myoblast development and protecting osteocytes through NF‐κB signaling, METTL21C also links osteosarcopenia to the METTL21C–NF‐κB axis [26]. Overall, these genetic variations establish an identifiable genetic basis for the degeneration of bone and muscle, linking osteoblast function, energy metabolism, and myogenesis to osteosarcopenia. Genomic Instability Genomic instability has been studied through animal models affecting DNA repair mechanisms. Ercc1−/Δ mutant murine mice models, lacking nucleotide excision repair, show osteoporosis‐like bone loss [27], and sarcopenia‐like muscle atrophy [28]. Similarly Muscle weakness and bone loss are signs of accelerated aging in PolgA animals deficient in mitochondrial DNA polymerase γ, which connects mitochondrial genomic instability to musculoskeletal deterioration [29]. Epigenetic Alterations By promoting adipogenesis and bone resorption, as well as hindering muscle regeneration and speeding up cellular aging, EZH2 disrupts musculoskeletal homeostasis and causes osteosarcopenia [30]. Furthermore, changes in gene expression in the phagocytosis and endocytosis pathways are found in transcriptome analyses of older women with osteosarcopenia, indicating common epigenetic processes [31]. Disabled Macroautophagy Autophagy, a cellular process of balancing degradation and recycling of cellular components, is vital for preserving bone and muscle integrity [32]. While a lack of autophagy (such as the loss of Drp1) results in oxidative stress, mitochondrial dysfunction, and muscle atrophy as people age, reduced autophagy impedes bone remodeling and promotes low bone mass [33, 34]. Deregulated Nutrient Sensing Disrupted nutrient sensing in aging affects bone and muscle health via the AKT/mTOR/FOXO pathway. Loss of Akt1/2 in muscle accelerates osteosarcopenia, while Foxo1/4 deletion reverses this [35]. Moreover, IGF‐1 and IL‐6 also regulate bone–muscle interaction through PI3K/AKT/mTOR and JAK/STAT signaling, linking movement to musculoskeletal aging [36]. Stem Cell Exhaustion With aging, there is a decline in proliferation of skeletal progenitor cells as confirmed by Single‐cell RNA sequencing [37]. Mesenchymal stem cell (MSC) therapy showed preservation of satellite cells, reducing inflammation, and enhancing bone density and structure in aged mice [38, 39]. Chronic Inflammation Josephson et al. found age‐associated inflammation as one of the cause of skeletal stem/progenitor cell (SSPC) dysfunction [40]. In muscle, cytokines like TNF‐α and IL‐6 increase protein breakdown and hinder regeneration, promoting sarcopenia [41]. A study identified new key cytokines LTA, CD40, CXCL6, CXCL10, DNER, and VEGFA as potential regulators of musculoskeletal health. LTA and CD40 were found protective while VEGFA increased in aging and correlated negatively with bone and muscle traits [42]. Dysbiosis Gut microbes support IGF‐1 signaling, crucial for musculoskeletal integrity [43]. Germ‐free mice show muscle weakness and altered bone mass, which improves with microbiota or SCFA restoration [44, 45]. Probiotics like Lactobacillus plantarum TWK10 enhance muscle function and bone quality in aged mice [46]. GLP‐1 Signaling GLP‐1 signaling enhances cellular proliferation and growth, which can be beneficial for musculoskeletal health. Based on the latest research, GLP‐1 receptor agonists have the ability to improve bone density and muscle mass in addition to their impacts on glucose and weight, highlighting their therapeutic significance for disorders including osteoporosis and sarcopenia [47]. Role of Fat Age‐related ectopic fat accumulation in bone marrow and muscle also contributes to osteosarcopenia by inhibiting osteoblast function, promoting cell death, and impairing muscle repair through inflammatory pathways and insulin resistance [48]. Moreover, inflammation from adipose tissue further aggravates bone loss and muscle wasting [49]. Interestingly, globular adiponectin may counteract these changes and offer therapeutic potential [50]. Role of Vitamin D Yang et al., 2019 showed that 1,25‐Dihydroxyvitamin D (1,25(OH)2 D3) plays a role in protection against age‐related osteoporosis by a novel VDR‐Ezh2‐p16 signal axis [51]. 1,25(OH)2 D3 deficient mice exhibited a sarcopenia phenotype, including muscular atrophy and decreased grip strength by promoting DNA damage‐induced GATA4 accumulation in muscles which upregulates Rela at thetranscriptional level to cause NF‐κB‐dependent SASP [52]. Higher vitamin D receptor (VDR) expression promotes muscle hypertrophy by triggering AKT/mTOR signaling, boosting protein synthesis and activating satellite cells [53]. Muscle and Bone Mechanics The mechanostat theory suggests that the force exerted by the muscle on the bone regulates bone formation or bone resorption [54, 55]. When muscle‐induced mechanical loading on bone is reduced, significant bone loss can occur [55]. In contrast, physical activity enhances both muscle and bone volume [56, 57]. Muscle‐Bone Crosstalk Myokines that support (irisin, IGF‐1, FGF2, decorin, IL‐6) or undermine (myostatin, FGF21) bone health play a role in muscle–bone crosstalk, whereas osteokines (osteocalcin, RANKL, sclerostin) reciprocally control muscle metabolism [58]. Myostatin Myostatin, a TGF‐β superfamily member, stimulates osteoclastogenesis and inhibits osteoblast function by suppressing the expression of miRNA‐218‐ Wnt signalling inhibitor pathway [59, 60]. Concurrently, myostatin inhibition via ActRIIB‐Fc enhances both tissues in mice, making it a promising therapeutic target in osteosarcopenia [61]. Irisin As a protective musculoskeletal factor, irisin, a cleaved adipomyokine, increases muscle growth and strength and stimulates osteoblast development via MAPK signaling [62, 63]. Reduced circulating levels are consistently associated with osteoporosis and sarcopenia [64, 65]. Animal studies have demonstrated that irisin deficiency impairs bone density and delays skeletal maturation [66]. RANKL Postmenopausal osteoporosis is characterized by high serum RANKL and RANKL/OPG ratio, which are produced by osteoblasts/osteocytes and counteracted by OPG [67, 68]. Importantly, RANKL is also expressed in skeletal muscle where it contributes to muscle atrophy via NF‐κB pathway activation and impaired myogenic differentiation [69]. Pharmacological inhibition of RANKL with agents such as denosumab has shown promise in improving both bone density and muscle strength in patients with osteosarcopenia [70]. Sclerostin Sclerostin (SOST) suppresses osteoblasts and promotes bone resorption by blocking Wnt/β‐catenin and BMP‐Smad signaling. It also reduces muscle hypertrophy and myogenesis [71]. Treatment of postmenopausal women with an blosozumab, an antibody targeted against sclerostin resulted in substantial increases in spine and hip BMD [72]. Others Endocrine disorders (mainly diabetes, abnormal thyroid function, sex steroids and growth hormone dysfunction), malnutrition, obesity, and use of corticosteroids are also associated with osteosarcopenia [24]. (Table 2). Table 2Summary table of osteosarcopenia pathophysiology.Pathophysiological mechanismKey effectsMicroRNA dysregulationAltered osteoblast/myoblast differentiation, increased atrophy genes (MuRF‐1, Atrogin‐1)Genetic polymorphismsIncreased risk via MYOSTATIN, METTL21C, SREBF1 gene variantsGenomic instabilityDNA repair defects cause bone loss and muscle atrophy (e.g., Ercc1 − /Δ, PolgA mice)Epigenetic alterationsMSC fate shifts to adipocytes, impaired regeneration (e.g., EZH2)Impaired autophagyDisrupted bone remodeling, mitochondrial dysfunction in muscleDeregulated nutrient sensingImpaired AKT/mTOR/FOXO signaling affecting bone‐muscle massStem cell exhaustionReduced satellite/BMSC proliferation, confirmed by scRNA‐seqChronic inflammationCytokines like TNF‐α, IL‐6 promote catabolism of bone and muscleGut dysbiosisLoss of SCFA and impaired IGF‐1 signaling reduce muscle and bone strength; conversely, probiotic supplementation (e.g., Lactobacillus plantarum TWK10) has been shown to enhance muscle function and bone quality, highlighting the therapeutic potential of microbiota modulationGLP‐1 signaling dysfunctionReduced anabolic effects on muscle and bone formationEctopic fat accumulationAdiposity induces inflammation, suppresses osteoblasts and myocytesVitamin D deficiencyDisrupted VDR pathways cause sarcopenia and bone lossMuscle‐bone mechanical unloadingReduced mechanical load leads to disuse‐related tissue lossMuscle‐bone crosstalk disruptionDisruption in irisin, myostatin, sclerostin, and osteocalcin signalingJohn Wiley & Sons, Ltd. Summary table of osteosarcopenia pathophysiology. Epidemiology and Global Burden Osteosarcopenia is getting more prevalent in the elderly population; it affects 18%–20% of older people and is more prevalent in women, mostly as a result of menopause and decreasing bone mineral density [73]. However, men are also affected, particularly those with endocrine or metabolic comorbidities. The prevalence of osteosarcopenia increases significantly with age, ranging from 5% to 37% in individuals over 65 years. This prevalence varies across regions, being higher in Oceania (22.9%), Asia (21.6%), and South America (20.8%), and lower in Europe (10.9%) and North America (15.7%) [5, 73]. This condition impairs mobility, increasing falls, fractures, hospitalizations, mortality, and healthcare burden with significant costs [13, 74, 75]. Due to the significant socioeconomic effects of osteosarcopenia, that include reduced quality of life, higher hospitalizations, and loss of independence, prompt identification and comprehensive treatment are crucial to reducing its burden [13, 67, 75] (Figure 1). Prevalence of osteosarcopenia across world regions. Oceania (22.9%), Asia (21.6%), and South America (20.8%) show the highest prevalence, whereas North America (15.7%) and Europe (10.9%) report lower prevalence. No Copyright is needed for this figure. Risk Factors and Comorbidities Osteosarcopenia is a multifactorial syndrome resulting from the interaction of multiple risk factors that collectively increase frailty in older adults. Physiological aging is the main factor, leading to hormonal, metabolic, and inflammatory changes [76]. The decline in anabolic hormones (estrogen, testosterone, growth hormone) disrupts bone remodeling and weakens muscle mass [76, 77]. In addition, a chronic low‐grade inflammation accelerates the degradation of both bone and muscle tissues [77]. Secondly, a sedentary lifestyle reduces the mechanical stimuli essential for maintaining musculoskeletal health. This inactivity is often worsened by pain, joint disorders, or social isolation [77]. At the same time, malnutrition particularly deficiencies in protein, calcium, and vitamin D contributes to the loss of bone and muscle mass [76, 77]. Certain chronic diseases such as type 2 diabetes, chronic kidney disease, and cardiovascular conditions also exacerbate this deterioration [78]. Polypharmacy, especially the prolonged use of glucocorticoids, increases bone resorption and muscle atrophy [76, 79]. Finally, hormonal and genetic factors influence individual susceptibility, particularly in postmenopausal women due to the drop in estrogen levels. This hormonal decline accelerates the loss of bone and muscle mass, while certain genetic predispositions may also impair bone and muscle metabolism [80]. (Figure 2). Risk factors for osteosarcopenia, including mitochondrial dysfunction, hormonal decline, chronic inflammation, chronic conditions, neurological disorders, genetic factors, old age, poor diet, physical inactivity or disability, and abdominal obesity. This figure was created using BioRender.com, and the appropriate BioRender publication license for journal use has been purchased. Diagnostic Challenges The diagnosis of osteosarcopenia remains a challenge due to the lack of international consensus criteria. To date, recommendations rely on separate guidelines; those of EWGSOP2 for sarcopenia [78, 81]. and IOF for osteoporosis [78]. However, there is no unified protocol to formally identify the coexistence of these two conditions [81, 82]. This gap makes clinical recognition of the syndrome difficult and may delay appropriate management of at‐risk patients [82]. Current diagnostic tools also present several technical and practical limitations. DEXA is the gold standard for evaluating BMD, but it does not evaluate muscle function or bone health. In contrast, BIA is more widely available but less accurate, particularly when hydration is altered [81, 83]. Functional tests, such as handgrip strength or gait speed, are widely used to assess muscle performance [84]. However, these tools sometimes lack sensitivity and can be skewed by the presence of other comorbidities, limiting their usefulness in a precise diagnostic context [81, 82, 84]. In response to these limitations, there is growing interest in integrating emerging biomarkers (such as myostatin, osteocalcin, or certain cytokines) [82, 83]. These biological biomarkers, in combination with clinical and functional data, could allow for better identification of osteosarcopenia patients, even at an early stage [75, 82]. A promising method for enhancing diagnosis and directing individualized treatment of osteosarcopenia is the use of composite indices that combine biological, clinical, and functional variables [83, 84]. Therapeutic Strategies Effective care of osteosarcopenia necessitates a dual strategy that targets bone fragility and muscle atrophy through combined lifestyle and pharmaceutical therapies, as shown in Figure 3. Schematic representation of key pathogenic pathways in osteosarcopenia and their aligned nutritional, pharmacological, and exercise‐based interventions. Non‐Pharmacological Approaches Resistance training, balance exercises, a healthy diet (protein, calcium, and vitamin D), fall prevention, along with improving bone density, muscle mass, strength, and quality of life are some examples of non‐pharmacological treatments. Progressive Resistance Training and Rehabilitation The Franconian Osteopenia and Sarcopenia Trial (FrOST) studies have shown that progressive resistance training combined with nutritional support (protein, calcium, and vitamin D) significantly improves bone density, lean mass, and muscle strength in osteosarcopenia [85]. High load activities, such as resistance and impact training, have significant osteogenic advantages, although physical training is an affordable strategy to improve musculoskeletal health through promoting muscle growth and bone formation [75]. Progressive resistance training is an efficient, evidence‐based method for preventing and treating osteosarcopenia because randomized controlled trials show that it promotes cardiovascular, cognitive, and metabolic health in along with strengthening bone and muscle structure [5]. Nutrition: Protein Intake, Vitamin D, Calcium Increasing protein intake to 1.2–1.5 g/kg/day especially in conjunction with resistance exercise enhances muscle mass, strength, and functional outcomes. Nutritional interventions are crucial in osteosarcopenia because aging reduces protein response, especially leucine a key stimulator of mTORC1 and muscle protein synthesis [5]. Whey protein, which is rich in leucine, appears especially effective. A 13‐week intervention of whey protein and vitamin D demonstrated increased lean mass, chair‐stand performance, and reduced inflammation in sarcopenic older adults [5]. Vitamin D improves musculoskeletal health and protein consumption; a daily intake of 800–2000 IU is advised to maintain appropriate levels, with greater dosages also assisting in reducing levels of pain and inflammation [4, 86]. Calcium is also essential, with 1000‐1300 mg/day advised to support bone mineralization and muscle contraction [4, 5]. Additionally, β‐hydroxy β‐methylbutyrate (HMB), a leucine metabolite, may help preserve muscle mass, though more evidence is needed in osteosarcopenia [5]. Overall, combining targeted supplementation with a balanced, anti‐inflammatory diet rich in omega‐3s and low in saturated fats can enhance musculoskeletal outcomes and reduce fracture risk [86]. Pharmacological Approaches Pharmacological therapy is frequently required in high‐risk patients, even if non‐pharmacological techniques are fundamental. While no single medication targets both bone and muscle, some osteoporosis medications increase muscle function and provide the best results when paired with exercise and diet [4, 86]. Anti‐Osteoporotic Agents: Bisphosphonates, Denosumab, Teriparatide Pharmacological management of osteosarcopenia is evolving, with most therapies targeting bone or muscle separately; current options include antiresorptives, anabolic agents, antisclerostin therapy, and hormonal treatments [5]. Although no drugs are currently approved specifically for osteosarcopenia, these agents may offer partial benefits. Additional pharmacological strategies under investigation include ACE inhibitors, anti‐myostatin antibodies, and ghrelin agonists, which may enhance muscle mass or strength, though their clinical efficacy in osteosarcopenia remains unproven [87]. More recently, selective androgen receptor modulators (SARMs), such as andarine, have gained attention for their dual anabolic effects on bone and muscle, with fewer side effects than traditional androgen therapies [78]. Ongoing research into combination therapies that simultaneously target both tissues may pave the way for more comprehensive pharmacological management of osteosarcopenia. Investigational Agents for Muscle Mass (e.g., SARMs, Myostatin Inhibitors) Beyond traditional antiresorptive and anabolic drugs, growing attention is being directed toward pharmacological agents that directly target the muscle component of osteosarcopenia. Several compounds have shown promise in stimulating muscle protein synthesis and counteracting sarcopenia. These include β‐receptor blockers, myostatin inhibitors, growth hormone, angiotensin‐converting enzyme (ACE) inhibitors, appetite stimulants, selective androgen receptor modulators (SARMs), ActRII antagonists, and other protein anabolic agents [88]. However, there remains a lack of long‐term safety data, and these effects have not consistently shown substantial improvements in muscular strength or function. Furthermore, routine clinical use has been limited due to concerns about endocrine, hepatic, and cardiovascular side effects [88]. Preclinical research is currently the only source of evidence for keratocan, and its clinical significance in osteosarcopenia is still being investigated. Although it is a promising target for the future, there is barely any data available regarding its safety and effectiveness, and these treatments are still in the experimental stage until well planned clinical trials are conducted [89]. However, while preclinical data are encouraging, further randomized clinical trials are required to establish efficacy and safety in human populations. (Figure 3). Integrated Management and Prevention Multidisciplinary care models, such as fall and fracture clinics (FFC), integrate assessment and treatment to reduce falls and fractures, highlighting the importance of coordinated management and patient adherence in osteosarcopenia [90]. Similarly, Arcidiacono et al. proposed the Hip‐Padua Osteosarcopenia (Hip‐POS) model, a fracture liaison service specifically designed for older adults with hip fractures. This program adopts a holistic strategy that begins with anti‐fracture pharmacotherapy and extends to include personalized nutrition support, assessment of muscle status, and rehabilitation for functional recovery. It also addresses often overlooked dimensions of post‐fracture care, thereby bridging critical gaps in secondary prevention. While initial results are promising, long‐term studies are needed to evaluate the program's impact on clinical outcomes, cost‐effectiveness, and its potential integration into broader healthcare systems [91]. Early detection of osteosarcopenia by the use of instruments such as SARC‐F, handgrip strength, gait speed, and DEXA allows for prompt diagnosis, reducing institutionalization, falls, and disability [92]. Future Gaps and Research Directions Although osteosarcopenia is increasingly recognized as a distinct clinical condition, several urgent gaps remain. The lack of epidemiological clarity is emphasized by the need for consistent definitions and surveillance techniques, since prevalence estimates vary widely between studies and diagnostic criteria vary across contexts and regions [73, 76]. Although there are few long‐term prospective studies, the mortality risk linked to osteosarcopenia is becoming more apparent, with recent meta‐analyses showing a 1.5‐fold increase [93]. The evidence for interventions is modest but encouraging. Although studies are usually brief and modest, resistance training regimens have been demonstrated to increase muscle mass and function as well as perhaps stabilize bone mineral density [94, 95]. Beyond conventional exercise, there aren't many high‐caliber studies evaluating multimodal approaches, including combination exercise, diet, and medication, especially when they target both muscle and bone simultaneously. Data from some groups, such cancer patients, also show increased susceptibility to osteosarcopenia, but this is not well understood outside of oncology settings [96]. Multidisciplinary, longitudinal, and interventional research that incorporates personalized medicine, digital health advances, and practical implementation strategies will be necessary to close these gaps. Discussion The most promising integrative pathophysiological pathways underlying osteosarcopenia highlight a complex interplay between chronic inflammation, miRNA dysregulation, and muscle‐bone crosstalk. Chronic low‐grade inflammation drives degradation in both muscle and bone tissues through cytokines that promote protein breakdown and hinder regeneration, thereby exacerbating sarcopenia and osteoporosis. Dysregulated microRNAs, such as miR‐29b, miR‐21, and miR‐128, modulate key signaling pathways involved in osteogenesis and muscle atrophy, serving as crucial molecular links in this syndrome. Meanwhile, muscle‐bone crosstalk through myokines and osteokines, including irisin, myostatin, and osteocalcin, establishes a bidirectional communication that influences musculoskeletal homeostasis. Recognizing these overlapping biological mechanisms moves understanding beyond isolated disorders towards a unified osteosarcopenia model that may unlock novel therapeutic targets by addressing both tissues simultaneously. Current diagnostic and therapeutic strategies remain largely siloed, relying on separate protocols and treatments for osteoporosis and sarcopenia without sufficient integration. The lack of standardized diagnostic criteria and dedicated biomarkers hampers early identification of osteosarcopenia, delaying appropriate management. Diagnostic tools such as DXA for bone density and functional tests for muscle strength are effective but insufficiently unified under an osteosarcopenia framework. Similarly, treatments primarily focus on either bone or muscle pathology—anti‐osteoporotic agents or muscle‐enhancing exercise—often missing opportunities for combined therapeutic benefit. The ideal model, exemplified by integrated care approaches like the Hip‐POS program and fracture‐fall clinics, advocates seamless multidisciplinary teams implementing combined pharmacological, nutritional, and exercise interventions tailored to the patient's musculoskeletal profile. This integration promises enhanced functional outcomes and reduced fall and fracture incidence. For clinical practice, general practitioners should prioritize early screening for osteosarcopenia in older adults by using combined assessments such as the SARC‐F questionnaire, handgrip strength, gait speed, and DXA scans. Recognizing the interconnected nature of bone and muscle decline encourages the adoption of holistic management plans beyond single‐disease treatment. Geriatricians and physiotherapists can play key roles by prescribing and supervising progressive resistance training alongside optimized nutrition to slow disease progression and preserve autonomy. Clinicians should also be aware of emerging pharmacological options like SARMs and anti‐myostatin therapies, though these require further validation. Overall, a shift toward integrated, multidisciplinary care considering musculoskeletal health as a unified entity is essential to improve quality of life and reduce healthcare burdens in aging populations. Conclusion Osteosarcopenia, a geriatric syndrome characterized by the coexistence of osteoporosis and sarcopenia, substantially increases the risk of falls, fractures, disability, and mortality in older adults. Even though thorough reviews have now confirmed its prevalence and negative effects, a lack of strong, integrated therapy approaches and inconsistent diagnostic frameworks hinder its practical application. Consensus definitions, extensive longitudinal investigations, and rigorous clinical trials assessing combination therapy involving drug, nutrition, and exercise should be prioritized in future research. The only way to reduce the increasing prevalence of osteosarcopenia and ultimately prolong life expectancy and maintain independence in older adults is to use such all‐encompassing, preventive, and interdisciplinary approaches. Author Contributions Javeria Taj: conceptualization, methodology, supervision, validation, project administration, writing – original draft, writing – review and editing, resources. Rabia Zafar: writing – review and editing, writing – original draft, validation. Joshua Ekouo: writing – original draft, writing – review and editing, validation. Ayesha Junaid: writing – original draft, writing – review and editing, validation. Dujardin Makeda: writing – original draft, writing – review and editing, validation. Kinza Latif: writing – original draft, writing – review and editing, validation. Hermann Yokolo: writing – original draft, conceptualization, methodology, validation, writing – review and editing, project administration, supervision, resources. Funding The authors have nothing to report. Ethics Statement The authors have nothing to report. Consent The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Transperency Statement The corresponding author (Hermann Yokolo) affirms that this manuscript presents an honest, accurate, and transparent account of the study in question; that no important aspect of the study has been omitted; and that any deviations from the study as it was planned (and, where applicable, registered) have been explained.